Search

Denufosol

A new drug application (NDA) was filed with the FDA in 2011, however, the second phase III clinical trial showed a lack of improvement in lung function for cystic fibrosis patients taking denufosol. … Denufosol was an inhaled drug used for the treatment of cystic fibrosis (CF), showing various improvements in lung function during a phase III clinical trial.

SO-101

SO-101(Silenor) is a low-dose oral tablet formulation of doxepin hydrochloride that is patent protected for its use in insomnia.

Ioglunide

Ioglunide is a small molecule drug. Ioglunide has a monoisotopic molecular weight of 806.86 Da.

Influenza B virus B/Darwin/7/2019 antigen (MDCK cell derived, propiolactone inactivated)

Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

Drostanolone propionate

Atl146e

ATL146e is an anti-inflammatory compounds which is an agonist of A2A adenosine receptors.

Domperidone

It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.

rhIGFBP-3

rhIGFBP-3 (recombinant human insulin-like growth factor binding protein-3) is Insmed’s proprietary anti-cancer compound that has demonstrated significant decreases in cancerous growth in several models … It is developed by Insmed and is currently under phase I of the clinical trial.

XP21279

XP21279 was under investigation in clinical trial NCT00914602 (An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects), administered in combination with [Carbidopa … XP21279 is a prodrug of [Levodopa], a dopamine precursor used in the management of Parkinson's disease.

Cannabidivarin

In October 2017 CBDV was given orphan designation by the European Medicines Agency for use in Rett Syndrome [L2952] and again in February 2018 for treatment of Fragile X Syndrome [L2951]. … , which is a member of a large family of ion channels that are involved in the onset and progression of several types of epilepsy.